

Ministry of Health

Health Programs and Delivery Division

Drug Submission Status

Report for July 2024

## Complete Streamlined Multiple-Source

Submissions for Off-Formulary Interchangeability

The Ministry of Health has received complete submissions for the following streamlined multiple-source drug products for Off-Formulary Interchangeability (OFI) designation. Subject to confirmation of Drug Identification Numbers (DIN) and prices by the manufacturers, as well as review and approval by the Executive Officer, these products may be designated as OFI drugs in a future Formulary update. Final OFI designation status will be communicated when the Formulary update is published on the Ministry website and via an HPDD Notice.

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Nora Pharma	NRA-Betahistine	Serc	BETAHISTINE HYDROCHLORIDE	8 mg	tablet	02544911
Nora Pharma	NRA-Betahistine	Serc	BETAHISTINE HYDROCHLORIDE	16 mg	tablet	02544938
Nora Pharma	NRA-Betahistine	Serc	BETAHISTINE HYDROCHLORIDE	24 mg	tablet	02544946
Auro Pharma Inc.	Auro-Dimethyl Fumarate	Tecfidera	DIMETHYL FUMARATE	120 mg	DR capsule	02540746
Auro Pharma Inc.	Auro-Dimethyl Fumarate	Tecfidera	DIMETHYL FUMARATE	240 mg	DR capsule	02540754
Jamp Pharma Corporation	Icatibant Injection	FIRAZYR	ICATIBANT	30 mg/ 3 mL	solution (subcutaneous)	02547562
Apotex Inc.	Apo-Lisdexamfetamine Capsules	Vyvanse	LISDEXAMFETAMINE DIMESYLATE	70 mg	capsule	02546728

Nora Pharma	NRA-Olanzapine ODT	Zyprexa Zydis	OLANZAPINE	20 mg	tablet	02536226
Mint Pharmaceutica Is Inc.	Mint- Posaconazole	Posanol	POSACONAZOLE	100 mg	DR tablet	02544644